Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers

Sayantan Kumar,Tom Earnest,Braden Yang,Deydeep Kothapalli,Andrew J. Aschenbrenner,Jason Hassenstab,Chengie Xiong,Beau Ances,John Morris,Tammie L. S. Benzinger,Brian A. Gordon,Philip Payne,Aristeidis Sotiras
2024-07-02
Abstract:INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze individual-level variation across ATN (amyloid-tau-neurodegeneration) imaging biomarkers. METHODS: We selected cross-sectional discovery (n = 665) and replication cohorts (n = 430) with available T1-weighted MRI, amyloid and tau PET. Normative modeling estimated individual-level abnormal deviations in amyloid-positive individuals compared to amyloid-negative controls. Regional abnormality patterns were mapped at different clinical group levels to assess intra-group heterogeneity. An individual-level disease severity index (DSI) was calculated using both the spatial extent and magnitude of abnormal deviations across ATN. RESULTS: Greater intra-group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD. Higher DSI was associated with worse cognitive function and increased risk of disease progression. DISCUSSION: Subject-specific abnormality maps across ATN reveal the heterogeneous impact of AD on the brain.
Neurons and Cognition,Machine Learning
What problem does this paper attempt to address?
This paper aims to analyze the heterogeneity in Alzheimer's disease (AD) through multi - modal normative modeling, especially in the imaging - based amyloid - tau - neurodegenerative (ATN) biomarkers. Specifically, the researchers used a deep - learning - based multi - modal normative framework to analyze the variation at the individual level, especially the differences between amyloid - positive individuals and amyloid - negative control groups. The main objectives of the study include: 1. **Evaluating the neuroanatomical and neuropathological variations among individual patients**: Assess the differences between individuals by identifying overlapping or distinct abnormal deviation patterns. 2. **Quantifying the within - group heterogeneity in the ADS clinical group**: Evaluate the within - group heterogeneity by analyzing the differences in ATN abnormal deviations among different participants. 3. **Estimating the disease severity index (DSI) for each ADS individual**: Calculate the DSI by combining the spatial extent of abnormal deviations and the magnitude of regional abnormal deviations. 4. **Examining the relationship between DSI and dementia severity, cognitive impairment, and disease progression risk**: Verify whether DSI is associated with the risk of cognitive decline and disease progression. The researchers hope that through these objectives, they can reveal the heterogeneity of the impact of AD on the brain and provide individualized disease assessment tools for precision medicine.